Individualization of caffeine supplementation in sports based on the analysis of heart rate variability (HRV)

Phase 1

• Conditions: Exercise performance; Diet and Nutrition - Other diet and nutrition disorders; Musculoskeletal - Normal musculoskeletal and cartilage development and function

• Registration Number: ACTRN12622000823774
• Lead Sponsor: Poznan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-06-10
• Last Update Posted: 20 June 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Healthy athletes and healthy volunteers

Exclusion Criteria

• lack of informed consent to participate in research,
• hypersensitivity to caffeine due to the polymorphism of the CYP1A2 gene
• diseases of the cardiovascular system,
• chronic disease impairing the functioning of the musculoskeletal system,
• diabetes,
• epilepsy,
• pregnancy,
• infections,
• inflammatory diseases,
• stroke history,
• oncological diseases,
• electronic life support systems (pacemakers, active prostheses, etc.)
• use of preparations that interact with caffeine, i.e. ephedrine, theophylline, and echinacea
• hypertension (over 140/90 mmHg)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in heart rate variability measured with a heart rate monitor.<br>[rest - 0-20 minutes continuous measurements HRV <br>after administration of caffeine/placebo- 20-80 minutes continuous measurements HRV.];Changes in muscle tension of the biceps femoris assessed with tensiomyography (TMG).[30 and 60 minutes after ingestion of 3 and 6 mg of caffeine or placebo<br><br>]

Secondary Outcome Measures

Name	Time	Method
.Changes in plasma caffeine concentrations.[30 and 60 minutes after ingestion of 3 and 6 mg of caffeine]